The Clinical Trial Accessibility Checklist: How Does Your Organization Measure Up?

7 Actions Biopharma Can Take To Create A More Accessible Environment For Clinical Trial Participants

 
• By Jessica Federer
  
Generate a summary of this article
Listen to this article
Beta

This year marks the 30th anniversary of the NIH revitalization act that required women and minorities to be included in clinical research in the US. Putting that into perspective, we have only really been collecting data at scale on women and minorities since the movie Jurassic Park was launched. If we want more people to participate in clinical trials, it is time to get real about reducing the burden of research on volunteers.

Number seven
• Source: Shutterstock

Clinical trials are not designed to help the study participants. They are designed to gather data to develop new treatments for people in the future. The biopharma industry depends on volunteers to participate in clinical trials that are not designed to help them. It is how we advance science and get new treatments to the world. Yet our industry is not doing enough to reduce the burden on volunteers in clinical trials.

Here are seven pragmatic actions the biopharma sector can take today to create a more accessible environment for clinical trial...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Diversity & Inclusion

  • How to create a story in Arc

     
    • By Kosh Naran

    Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, In Vivo investigates.

  • Medtechs Are Fully Engaged In Climate Change: ‘They Have No Choice’

     
    • By Ashley Yeo

    The E in ESG: SUDs, reuse, disposables, refurbishing, reprocessed devices? Multiple panelists at the 2024 MedTech Forum addressed the role medtech manufacturers should have in the climate change challenge.

  • 16 Key Trends Reshaping The Future Of Medtech

     
    • By Ashley Yeo

    Record attendance at the 2024 MedTech Forum in Vienna heard industry leaders voice optimism grounded in realism about future developments for Europe’s medtech industry, markets and delivery of care to patients. In Vivo filtered out 16 trends to watch.

  • South Korea Sees Pharma Leadership Transition

     
    • By Mainbayar Badarch

    Leadership succession is proceeding within South Korean pharmaceutical corporations such as Daiichi Sankyo Korea, Astellas Pharma Korea, Kyowa Kirin Korea as well as MSD Korea.  

More from ESG